Drug intelligence / Profile preview

recombinant BCG

Development stage: Phase 2
Lead developer: ImmunityBio
Modality: Vaccines & Immunotherapeutics
Administration: Intravesical

Overview

Recombinant BCG (rBCG) is a modified version of Bacillus Calmette-Guerin (BCG) developed to address shortages of standard BCG. It is being developed by ImmunityBio, often in combination with its FDA-approved immunotherapy ANKTIVA (nogapendekin alfa inbakicept-pmln), for various cancer indications, particularly bladder cancer. ImmunityBio has secured manufacturing and supply from the Serum Institute of India (SII) to support its clinical trials and an Expanded Access Program in the U.S.

Brand names: VPM1002BCVPM-1002BCVPM 1002BC
Other names: recombinant BCG vaccine

Targets

TLR2 (Toll-like Receptor 2)NOD2 (Nucleotide-binding oligomerization domain-containing protein 2)TLR4 (Toll-like receptor 4)

Beyond the preview

Go deeper on recombinant BCG.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on recombinant BCG.

Explore the full profile